Seeking Alpha

Novartis licenses more ImmunoGen technology

  • Novartis (NVS) has licensed the exclusive right to use ImmunoGen's (IMGN) ADC technology to develop anti-cancer drugs.
  • This is the second time that Novartis has made such a move - under a 2010 agreement, the Swiss giant pays an upfront fee to ImmunoGen for each license, milestone payments worth as much as $200M, and any royalties on sales. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: